Recursion Pharmaceuticals (RXRX) Q1 2026 earnings summary

Executive summary

• Leveraged an AI-driven platform to accelerate drug discovery and development, achieving clinical proof-of-concept for REC-4881 in FAP and advancing multiple wholly owned and partnered programs with defined milestones over the next 12–18 months.

• Achieved over $500 million in partner inflows and 10+ milestones, validating the AI engine's ability to generate novel targets and molecules.

• Cash, cash equivalents, and restricted cash totaled $665.2 million as of March 31, 2026, extending runway into early 2028 with a 30% year-over-year reduction in operating expenses.

• Net loss for Q1 2026 narrowed to $117.5 million from $202.5 million in Q1 2025, reflecting improved operating efficiency.

• Appointment of Dr. Vicki Goodman as Chief Medical Officer to lead clinical development and regulatory strategy.

Financial highlights

• Total revenue for Q1 2026 was $6.5 million, down 56% year-over-year due to lower milestone recognition.

• Operating costs and expenses decreased 35% year-over-year to $135.0 million, with R&D expenses down 32% to $87.9 million and G&A expenses down 37% to $34.6 million.

• Cash operating expense for Q1 2026 was $85.1 million, down from $120.2 million in Q1 2025.

• Net loss per share improved to $(0.22) from $(0.50) year-over-year, with weighted average shares outstanding at 529.3 million.

• Cash runway projected into early 2028 based on current expense levels and partnership inflows, with no additional financing required.

Outlook and guidance

• Multiple clinical and regulatory milestones anticipated in 2026 and 2027, including Phase 2 data, FDA engagement for key programs, and further partnership achievements.

• Reiterated guidance of less than $390 million operational cash burn through 2026, supporting a cash runway into early 2028.

• Ongoing need for additional capital in the future to fund operations and potential commercialization.